Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Eptifibatide

FDA-approved product (injectable, injection), marketed as Eptifibatide, Integrilin.

Registered studies
35
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Eptifibatide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute coronary syndrome
  • Acute myocardial infarction
  • Intermediate coronary syndrome
  • Myocardial infarction
  • Recurrent thrombophlebitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
FDA pharmacologic class
Platelet Aggregation Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA67.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

35registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Eptifibatide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Eptifibatide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis

    NCT07347626 · start 2026-03-01

    Registered record
    Registry ID
    NCT07347626
    Conditions
    Acute Ischemic Stroke
    Interventions
    Eptifibatide (Integrilin); Standard Medical Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-03-01
    Completion
    2029-12-31
    Enrolment
    786

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Ischemic Stroke
    InterventionEptifibatide (Integrilin); Standard Medical Therapy
    PhasePhase 3
    Registry statusNot yet recruiting

  • Platelet Function in Patients With Ischemic Stroke Treated With Anti-thrombotic or Thrombolytic

    NCT05415150 · start 2022-02-18

    Registered record
    Registry ID
    NCT05415150
    Conditions
    Acute Ischemic Stroke
    Interventions
    Thrombolytic Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2022-02-18
    Completion
    2024-05-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Ischemic Stroke
    InterventionThrombolytic Agent
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Multi-arm Optimization of Stroke Thrombolysis

    NCT03735979 · start 2019-10-15

    Registered record
    Registry ID
    NCT03735979
    Conditions
    Acute Ischemic Stroke
    Interventions
    Argatroban; Eptifibatide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-10-15
    Completion
    2024-10-31
    Enrolment
    514

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Ischemic Stroke
    InterventionArgatroban; Eptifibatide; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH)

    NCT03844594 · start 2019-04-06

    Registered record
    Registry ID
    NCT03844594
    Conditions
    Acute Ischemic Stroke
    Interventions
    Eptifibatide Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-04-06
    Completion
    2020-12-31
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Ischemic Stroke
    InterventionEptifibatide Injection
    PhasePhase 3
    Registry statusUnknown

  • Pharmacologic Treatment of Myocardial Ischemia Detected by Intracoronary ECG

    NCT03383393 · start 2018-01-03

    Registered record
    Registry ID
    NCT03383393
    Conditions
    Coronary Ischemia
    Interventions
    Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-01-03
    Completion
    2019-12-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Ischemia
    InterventionIntracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)
    PhaseNot recorded
    Registry statusUnknown

  • Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

    NCT02925923 · start 2016-11-01

    Registered record
    Registry ID
    NCT02925923
    Conditions
    Acute Coronary Syndrome; Angina, Unstable
    Interventions
    Ticagrelor; Eptifibatide; Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-11-01
    Completion
    2018-12-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome; Angina, Unstable
    InterventionTicagrelor; Eptifibatide; Clopidogrel
    PhasePhase 2
    Registry statusCompleted

  • Co-administration of Iloprost and Eptifibatide in Septic Shock Patients

    NCT02204852 · start 2014-09

    Registered record
    Registry ID
    NCT02204852
    Conditions
    Septic Shock
    Interventions
    Iloprost+eptifibatide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-09
    Completion
    2016-08
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionIloprost+eptifibatide; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

    NCT01919723 · start 2014-02

    Registered record
    Registry ID
    NCT01919723
    Conditions
    Acute Coronary Syndrome
    Interventions
    Ticagrelor; Eptifibatide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-02
    Completion
    2015-12
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionTicagrelor; Eptifibatide
    PhasePhase 2
    Registry statusCompleted

  • Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?

    NCT01991366 · start 2013-10

    Registered record
    Registry ID
    NCT01991366
    Conditions
    ST-elevation Myocardial Infarction; Acute Myocardial Infarction
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2013-10
    Completion
    2021-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionST-elevation Myocardial Infarction; Acute Myocardial Infarction
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)

    NCT01977456 · start 2013-09

    Registered record
    Registry ID
    NCT01977456
    Conditions
    Stroke; Brain Infarction
    Interventions
    Eptifibatide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-09
    Completion
    2015-04
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke; Brain Infarction
    InterventionEptifibatide
    PhasePhase 2
    Registry statusCompleted

  • Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome

    NCT01994941 · start 2013-08

    Registered record
    Registry ID
    NCT01994941
    Conditions
    Acute Coronary Syndrome
    Interventions
    Clopidogrel; Ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-08
    Completion
    2015-08
    Enrolment
    133

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionClopidogrel; Ticagrelor
    PhasePhase 4
    Registry statusCompleted

  • Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis

    NCT01532544 · start 2012-06

    Registered record
    Registry ID
    NCT01532544
    Conditions
    Pneumonia
    Interventions
    Ilomedin and Integrilin; low molecular weight heparin.
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-06
    Completion
    2014-03
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia
    InterventionIlomedin and Integrilin; low molecular weight heparin.
    PhasePhase 2
    Registry statusTerminated

  • Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

    NCT01522417 · start 2012-04

    Registered record
    Registry ID
    NCT01522417
    Conditions
    Myocardial Infarction; Acute Coronary Syndromes; Unstable Angina
    Interventions
    Short Tirofiban; Eptifibatide; Long Tirofiban
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-04
    Completion
    2019-03
    Enrolment
    535

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction; Acute Coronary Syndromes; Unstable Angina
    InterventionShort Tirofiban; Eptifibatide; Long Tirofiban
    PhasePhase 2
    Registry statusCompleted

  • Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX

    NCT01433627 · start 2011-10

    Registered record
    Registry ID
    NCT01433627
    Conditions
    Acute Coronary Syndromes; STEMI; NSTEMI
    Interventions
    trans-radial and short-term bivalirudin; trans-radial and long-term bivalirudin infusion; trans-radial and standard of care pharmacology; Trans-femoral and Short-term bivalirudin; trans-femoral and long-term bivalirudin infusion; trans-femoral and standard of care pharmacology
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2011-10
    Completion
    2015-12
    Enrolment
    7,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndromes; STEMI; NSTEMI
    Interventiontrans-radial and short-term bivalirudin; trans-radial and long-term bivalirudin infusion; trans-radial and standard of care pharmacology; Trans-femoral and Short-term bivalirudin +2 more
    PhasePhase 3
    Registry statusUnknown

  • Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

    NCT01076764 · start 2010-04

    Registered record
    Registry ID
    NCT01076764
    Conditions
    Acute Coronary Syndrome
    Interventions
    Otamixaban; Placebo (for Otamixaban); UFH; Placebo (for UFH); Eptifibatide; Placebo (for Eptifibatide)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-04
    Completion
    2013-05
    Enrolment
    13,220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionOtamixaban; Placebo (for Otamixaban); UFH; Placebo (for UFH) +2 more
    PhasePhase 3
    Registry statusCompleted